Channeling Hope in the Expanding Landscape of Therapy for Pulmonary Hypertension: Potential Role for Piezo2

doi:10.1161/HYPERTENSIONAHA.125.24570

Editorial

. 2025 Apr;82(4):598-600.

doi: 10.1161/HYPERTENSIONAHA.125.24570. Epub 2025 Mar 19.

Channeling Hope in the Expanding Landscape of Therapy for Pulmonary Hypertension: Potential Role for Piezo2

Jochen Steppan¹, Dan E Berkowitz²

Affiliations

¹ School of Medicine, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, MD (J.S.).
² Heersink School of Medicine, Department of Anesthesiology and Perioperative Medicine, Univeristy of Alabama at Birmingham (D.E.B.).

PMID: 40106532
PMCID: PMC12117469
DOI: 10.1161/HYPERTENSIONAHA.125.24570

Editorial

Channeling Hope in the Expanding Landscape of Therapy for Pulmonary Hypertension: Potential Role for Piezo2

Jochen Steppan et al. Hypertension. 2025 Apr.

. 2025 Apr;82(4):598-600.

doi: 10.1161/HYPERTENSIONAHA.125.24570. Epub 2025 Mar 19.

Authors

Jochen Steppan¹, Dan E Berkowitz²

Affiliations

¹ School of Medicine, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, MD (J.S.).
² Heersink School of Medicine, Department of Anesthesiology and Perioperative Medicine, Univeristy of Alabama at Birmingham (D.E.B.).

PMID: 40106532
PMCID: PMC12117469
DOI: 10.1161/HYPERTENSIONAHA.125.24570

No abstract available

PubMed Disclaimer

Conflict of interest statement

None.

Figures

See this image and copyright information in PMC

Comment on

Deficiency of Endothelial Piezo2 Impairs Pulmonary Vascular Angiogenesis and Predisposes Pulmonary Hypertension.
Wei F, Lin Z, Lu W, Luo H, Feng H, Liu S, Zhang C, Zheng Y, Chen J, Mo S, Wang C, Zhang Z, Feng W, Zhu J, Yang Q, Du M, Kong W, Liu A, Lai J, Li X, Wu X, Lai N, Chen Y, Yang K, Wang J. Wei F, et al. Hypertension. 2025 Apr;82(4):583-597. doi: 10.1161/HYPERTENSIONAHA.124.22948. Epub 2025 Jan 6. Hypertension. 2025. PMID: 39758000

References

1. Madonna R, Biondi F. Sotatercept: new drug on the horizon of pulmonary hypertension. Vascul Pharmacol. 2024;157:107442. doi: 10.1016/j.vph.2024.107442 - DOI - PubMed
1. Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grunig E, et al.; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388:1478–1490. doi: 10.1056/NEJMoa2213558 - DOI - PubMed
1. Steppan J, Wang H, Nandakumar K, Gadkari M, Poe A, Pak L, Brady T, Berkowitz DE, Shimoda LA, Santhanam L. LOXL2 inhibition ameliorates pulmonary artery remodeling in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2024;327:L423–L438. doi: 10.1152/ajplung.00327.2023 - DOI - PMC - PubMed
1. Shen Y, Goncharov DA, Pena A, Baust J, Chavez Barragan A, Ray A, Rode A, Bachman TN, Chang B, Jiang L, et al. Cross-talk between TSC2 and the extracellular matrix controls pulmonary vascular proliferation and pulmonary hypertension. Sci Signal. 2022;15:eabn2743. doi: 10.1126/scisignal.abn2743 - DOI - PMC - PubMed
1. Kawut SM, Feng R, Ellenberg SS, Zamanian R, Bull T, Chakinala M, Mathai SC, Hemnes A, Lin G, Doyle M, et al. Pulmonary hypertension and anastrozole (PHANTOM): a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2024;210:1143–1151. doi: 10.1164/rccm.202402-0371OC - DOI - PMC - PubMed

Publication types

Actions
Actions

Grants and funding

R56 HL169285/HL/NHLBI NIH HHS/United States

LinkOut - more resources

Full Text Sources

[1] Madonna R, Biondi F. Sotatercept: new drug on the horizon of pulmonary hypertension. Vascul Pharmacol. 2024;157:107442. doi: 10.1016/j.vph.2024.107442 - DOI - PubMed

[2] Madonna R, Biondi F. Sotatercept: new drug on the horizon of pulmonary hypertension. Vascul Pharmacol. 2024;157:107442. doi: 10.1016/j.vph.2024.107442 - DOI - PubMed

[3] Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grunig E, et al.; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388:1478–1490. doi: 10.1056/NEJMoa2213558 - DOI - PubMed

[4] Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grunig E, et al.; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388:1478–1490. doi: 10.1056/NEJMoa2213558 - DOI - PubMed

[5] Steppan J, Wang H, Nandakumar K, Gadkari M, Poe A, Pak L, Brady T, Berkowitz DE, Shimoda LA, Santhanam L. LOXL2 inhibition ameliorates pulmonary artery remodeling in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2024;327:L423–L438. doi: 10.1152/ajplung.00327.2023 - DOI - PMC - PubMed

[6] Steppan J, Wang H, Nandakumar K, Gadkari M, Poe A, Pak L, Brady T, Berkowitz DE, Shimoda LA, Santhanam L. LOXL2 inhibition ameliorates pulmonary artery remodeling in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2024;327:L423–L438. doi: 10.1152/ajplung.00327.2023 - DOI - PMC - PubMed

[7] Shen Y, Goncharov DA, Pena A, Baust J, Chavez Barragan A, Ray A, Rode A, Bachman TN, Chang B, Jiang L, et al. Cross-talk between TSC2 and the extracellular matrix controls pulmonary vascular proliferation and pulmonary hypertension. Sci Signal. 2022;15:eabn2743. doi: 10.1126/scisignal.abn2743 - DOI - PMC - PubMed

[8] Shen Y, Goncharov DA, Pena A, Baust J, Chavez Barragan A, Ray A, Rode A, Bachman TN, Chang B, Jiang L, et al. Cross-talk between TSC2 and the extracellular matrix controls pulmonary vascular proliferation and pulmonary hypertension. Sci Signal. 2022;15:eabn2743. doi: 10.1126/scisignal.abn2743 - DOI - PMC - PubMed

[9] Kawut SM, Feng R, Ellenberg SS, Zamanian R, Bull T, Chakinala M, Mathai SC, Hemnes A, Lin G, Doyle M, et al. Pulmonary hypertension and anastrozole (PHANTOM): a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2024;210:1143–1151. doi: 10.1164/rccm.202402-0371OC - DOI - PMC - PubMed

[10] Kawut SM, Feng R, Ellenberg SS, Zamanian R, Bull T, Chakinala M, Mathai SC, Hemnes A, Lin G, Doyle M, et al. Pulmonary hypertension and anastrozole (PHANTOM): a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2024;210:1143–1151. doi: 10.1164/rccm.202402-0371OC - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Channeling Hope in the Expanding Landscape of Therapy for Pulmonary Hypertension: Potential Role for Piezo2

Affiliations

Channeling Hope in the Expanding Landscape of Therapy for Pulmonary Hypertension: Potential Role for Piezo2

Authors

Affiliations

Conflict of interest statement

Figures

Comment on

Similar articles

References

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources